Akanda (AKAN) Competitors $1.58 -0.01 (-0.63%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends AKAN vs. ENSC, MYNZ, SPRC, CYCN, BFRI, EGRX, ADXN, AIMD, NLSP, and OBSVShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Ensysce Biosciences (ENSC), Mainz Biomed (MYNZ), SciSparc (SPRC), Cyclerion Therapeutics (CYCN), Biofrontera (BFRI), Eagle Pharmaceuticals (EGRX), Addex Therapeutics (ADXN), Ainos (AIMD), NLS Pharmaceutics (NLSP), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Ensysce Biosciences Mainz Biomed SciSparc Cyclerion Therapeutics Biofrontera Eagle Pharmaceuticals Addex Therapeutics Ainos NLS Pharmaceutics ObsEva Akanda (NASDAQ:AKAN) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Which has more volatility and risk, AKAN or ENSC? Akanda has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Does the MarketBeat Community believe in AKAN or ENSC? Ensysce Biosciences received 3 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformAkandaN/AN/AEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Is AKAN or ENSC more profitable? Akanda has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Akanda's return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A Ensysce Biosciences -179.26%-292.81%-158.83% Does the media refer more to AKAN or ENSC? In the previous week, Ensysce Biosciences had 2 more articles in the media than Akanda. MarketBeat recorded 2 mentions for Ensysce Biosciences and 0 mentions for Akanda. Akanda's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score. Company Overall Sentiment Akanda Neutral Ensysce Biosciences Neutral Do insiders and institutionals hold more shares of AKAN or ENSC? 1.0% of Akanda shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings and valuation, AKAN or ENSC? Ensysce Biosciences has higher revenue and earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$2.16M1.05-$32.28MN/AN/AEnsysce Biosciences$2.23M4.72-$10.61M-$27.44-0.29 SummaryEnsysce Biosciences beats Akanda on 6 of the 11 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.26M$1.19B$5.45B$9.22BDividend YieldN/AN/A5.36%3.97%P/E RatioN/A34.8388.6817.51Price / Sales1.056.711,257.3279.84Price / CashN/A9.9644.6537.70Price / Book-0.022.065.034.72Net Income-$32.28M-$53.10M$118.07M$224.62M7 Day Performance-5.39%-0.25%3.07%1.77%1 Month Performance-3.66%-0.89%4.33%4.41%1 Year Performance-94.73%-5.65%26.81%21.97% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.58-0.6%N/A-94.6%$2.26M$2.16M0.00110Positive NewsENSCEnsysce Biosciences0.0152 of 5 stars$6.96-7.1%N/A-51.6%$9.09M$2.23M-0.2510News CoverageGap DownMYNZMainz Biomed1.9544 of 5 stars$4.53+5.8%$120.00+2,549.0%-89.6%$9.07M$917,203.00-0.0730Positive NewsGap UpSPRCSciSparc0.3279 of 5 stars$0.87+6.7%N/A-82.8%$9.00M$1.75M0.004Gap UpCYCNCyclerion TherapeuticsN/A$3.30+0.3%N/A-14.5%$8.94M$1.62M0.0030Positive NewsGap UpBFRIBiofrontera3.1306 of 5 stars$1.14+1.8%$7.00+514.0%-37.0%$8.83M$35.36M-0.5070News CoverageEGRXEagle PharmaceuticalsN/A$0.65+16.1%N/A-83.0%$8.44M$257.55M0.00100Gap DownADXNAddex Therapeutics2.5033 of 5 stars$7.81+3.8%$30.00+284.3%+4.1%$8.27M$556,045.00-22.9630Positive NewsGap UpAIMDAinos1.2489 of 5 stars$0.58-17.6%N/A-39.0%$8.24M$40,633.000.0040Gap UpNLSPNLS PharmaceuticsN/A$2.10-9.5%N/A+294.6%$8.01MN/A0.006Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150 Related Companies and Tools Related Companies ENSC Competitors MYNZ Competitors SPRC Competitors CYCN Competitors BFRI Competitors EGRX Competitors ADXN Competitors AIMD Competitors NLSP Competitors OBSV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKAN) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
